Literature DB >> 23427176

Young Australian adults with NF1 have poor access to health care, high complication rates, and limited disease knowledge.

Emily C Oates1, Jonathan M Payne, Sheryl L Foster, Nigel F Clarke, Kathryn N North.   

Abstract

Neurofibromatosis type 1 (NF1) is a multisystem disease associated with a lifelong risk of debilitating and potentially life-limiting complications, however many adults with NF1 have no regular health surveillance. We interviewed and examined 17 young adults with NF1 between the ages of 25 and 33. Most had not been assessed for NF1-related complications within the previous 8 years, including patients with known serious vascular complications, for example, renal artery stenosis. Acute and/or chronic pain, particularly back and plexiform-related pain were common symptoms, and despite a significant impact on quality of life, was untreated in most instances. Symptom and examination-directed imaging revealed serious complications in 41% of the cohort. These included severe spinal cord compression (two cases), a highly SUV avid lesion suggestive of malignancy (one case), and a Juvenile Pilocytic Astrocytoma in a patient without any previous NF1-related complications. Few study participants had a good understanding of NF1, its associated risks and complications, and many had not sought appropriate medical advice as questions or problems arose. NF1-related cognitive deficits in some participants, and the lack of a clear source of expert medical advice for adults with NF1 likely contributed to poor health surveillance and management in this population. Overall, these findings suggest that many Australian adults with NF1 are at risk of serious and life-threatening medical complications, but are not accessing and receiving adequate health care. Access to multidisciplinary adult clinics that specialize in NF1 may address many of the unmet health needs of young adults with NF1.
Copyright © 2013 Wiley Periodicals, Inc.

Entities:  

Mesh:

Year:  2013        PMID: 23427176     DOI: 10.1002/ajmg.a.35840

Source DB:  PubMed          Journal:  Am J Med Genet A        ISSN: 1552-4825            Impact factor:   2.802


  11 in total

1.  Propranolol Specifically Suppresses the Viability of Tumorous Schwann Cells Derived from Plexiform Neurofibromas In Vitro.

Authors:  Ziang Zou; Linna Guo; Victor Mautner; Ralf Smeets; Lan Kiuwe; Reinhard E Friedrich
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  The Impact of Neurofibromatosis Type 1 on the Health and Wellbeing of Australian Adults.

Authors:  Hilda A Crawford; Belinda Barton; Meredith J Wilson; Yemima Berman; Valerie J McKelvey-Martin; Patrick J Morrison; Kathryn N North
Journal:  J Genet Couns       Date:  2015-04-19       Impact factor: 2.537

3.  Knowledge and Self-Esteem of Individuals with Neurofibromatosis Type 1 (NF1).

Authors:  Kayla Rosnau; S Shahrukh Hashmi; Hope Northrup; John Slopis; Sarah Noblin; Myla Ashfaq
Journal:  J Genet Couns       Date:  2016-11-04       Impact factor: 2.537

4.  Neurocognitive outcomes in neurofibromatosis clinical trials: Recommendations for the domain of attention.

Authors:  Karin S Walsh; Jennifer Janusz; Pamela L Wolters; Staci Martin; Bonita P Klein-Tasman; Mary Anne Toledo-Tamula; Heather L Thompson; Jonathan M Payne; Kristina K Hardy; Peter de Blank; Claire Semerjian; Laura Schaffner Gray; Sondra E Solomon; Nicole Ullrich
Journal:  Neurology       Date:  2016-08-16       Impact factor: 9.910

5.  Quality of Life in Adults with Neurofibromatosis 1 in Brazil.

Authors:  Natália Parenti Bicudo; Balduíno Ferreira de Menezes Neto; Lucimar Retto da Silva de Avó; Carla Maria Ramos Germano; Débora Gusmão Melo
Journal:  J Genet Couns       Date:  2016-03-05       Impact factor: 2.537

6.  Nilotinib is more potent than imatinib for treating plexiform neurofibroma in vitro and in vivo.

Authors:  Jiang Wei; Marcus Freytag; Yvonne Schober; Wolfgang A Nockher; Victor F Mautner; Reinhard E Friedrich; Paul W Manley; Lan Kluwe; Andreas Kurtz
Journal:  PLoS One       Date:  2014-10-23       Impact factor: 3.240

Review 7.  Skeletal muscle and motor deficits in Neurofibromatosis Type 1.

Authors:  M A Summers; K G Quinlan; J M Payne; D G Little; K N North; A Schindeler
Journal:  J Musculoskelet Neuronal Interact       Date:  2015-06       Impact factor: 2.041

8.  Worries and needs of adults and parents of adults with neurofibromatosis type 1.

Authors:  Andre B Rietman; Hanneke van Helden; Pauline H Both; Walter Taal; Jeroen S Legerstee; AnneLoes van Staa; Henriette A Moll; Rianne Oostenbrink; Agnies M van Eeghen
Journal:  Am J Med Genet A       Date:  2018-05       Impact factor: 2.802

9.  Care of adults with neurofibromatosis type 1: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG).

Authors:  Douglas R Stewart; Bruce R Korf; Katherine L Nathanson; David A Stevenson; Kaleb Yohay
Journal:  Genet Med       Date:  2018-04-26       Impact factor: 8.822

10.  A qualitative study of the impact of plexiform neurofibromas on need fulfilment in adults with neurofibromatosis type 1.

Authors:  Alice Heaney; Jeanette Wilburn; Shannon Langmead; Jaishri Blakeley; Susan Huson; Carly Jim; Stephen P McKenna
Journal:  SAGE Open Med       Date:  2019-02-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.